A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management

A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management

Abstract Background High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. We aime...

Full description

Bibliographic Details
Main Authors: Melissa Bradbury, Eva Borràs, Marta Vilar, Josep Castellví, José Luis Sánchez-Iglesias, Assumpció Pérez-Benavente, Antonio Gil-Moreno, Anna Santamaria, Eduard Sabidó
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Journal of Translational Medicine
Subjects:
High-grade serous ovarian cancer
Proteomics
Biomarker
Prediction
Treatment
Online Access:https://doi.org/10.1186/s12967-022-03816-7

Internet

https://doi.org/10.1186/s12967-022-03816-7

Similar Items